Quinazoline Based Dual Inhibitors of EGFR and VEGFR as Potential Anti-proliferative Agents-A Review

AbstractIt has been established that the overexpression of tyrosine kinase inhibitors, EGFR and VEGFR is the primary factor contributing to the development and spread of carcinomas, including pancreatic, lung, and breast cancers. Quinazoline nucleus is a distinct and flexible scaffold with a broad range of pharmacological action, particularly in the area of tyrosine kinase inhibitors, where the US Food and Drug Administration has approved more than twenty small molecule inhibitors in the past 20 years. Quinazoline derivatives are effective inhibitors of EGFR and VEGFR, which are key targets in cancer therapy. Their ability to inhibit the action of these receptors aids in the control of tumour growth and metastasis, making them essential tools in the treatment of many cancers. Some novel quinazoline and quinazolinone derivatives which act as EGFR and VEGFR dual inhibitors are discussed in this review.KeywordsEGFR, VEGFR, cancer, quinazoline, tyrosine kinase.